Transglutaminase 3 crosslinks the secreted gel-forming mucus component Mucin-2 and stabilizes the colonic mucus layer

Jack D. A. Sharpen1, Brendan Dolan1, Elisabeth E. L. Nyström1, George M. H. Birchenough1, Liisa Arike1, Beatriz Martinez-Abad1, Malin E. V. Johansson1, Gunnar C. Hansson1 & Christian V. Recktenwald1

The colonic mucus layer is organized as a two-layered system providing a physical barrier against pathogens and simultaneously harboring the commensal flora. The factors contributing to the organization of this gel network are not well understood. In this study, the impact of transglutaminase activity on this architecture was analyzed. Here, we show that transglutaminase TGM3 is the major transglutaminase-isoform expressed and synthesized in the colon. Furthermore, intrinsic extracellular transglutaminase activity in the secreted mucus was demonstrated in vitro and ex vivo. Absence of this acyl-transferase activity resulted in faster degradation of the major mucus component the MUC2 mucin and changed the biochemical properties of mucus. Finally, TGM3-deficient mice showed an early increased susceptibility to Dextran Sodium Sulfate-induced colitis. Here, we report that natural iso-peptide cross-linking by TGM3 is important for mucus homeostasis and protection of the colon from inflammation, reducing the risk of colitis.
The epithelium in the intestinal tract is covered by mucus that provides protection from luminal challenges and bacterial infiltration. Despite the similar proteome composition, the organization of the mucus gel network differs considerably between the small and large intestine. Whereas small intestinal mucus is non-attached, the colonic mucus is a two-layered system with an attached, bacteria-free inner layer and an outer layer harboring the commensal flora. The molecular mechanisms determining these structural differences are not well understood. The predominant component of mucus is the gel-forming MUC2 mucin which is synthesized by intestinal goblet cells. It has been shown that Muc2-/- mice develop spontaneous colitis, a pre-stage of colitis-associated carcinoma. Furthermore, the MUC2 levels in patients suffering from active ulcerative colitis (UC) are decreased when compared to healthy control patients.

The human MUC2 monomer consists of 5,130 amino acids organized in three complete and one partial von Willebrand D (vWD) domains in the N-terminal part followed by the first CysD domain, and two Proline-Threonine- and Serine-rich (PTS) sequences that are separated by the second CysD domain. The C-terminus harbors a fourth vWD domain, two vWC domains, and the cysteine-knot. During its transport through the endoplasmic reticulum and the Golgi-network MUC2 monomers first form C-terminal dimeric and in the later stages of the secretory pathway N-terminal dimers or trimers. Furthermore, the PTS sequences become heavily O-glycosylated to form mucin domains. This post-translational modification (PTM) shifts the mass of MUC2 from roughly 650 kDa to more than 2.5 MDa. During the later stages of the secretory pathway isopeptide bonds are introduced probably contributing to the insolubility of MUC2 in chaotropic salts like guanidinium chloride. An enzyme family which can catalyze these natural protein cross-links are the transglutaminases (TGM).

Transglutaminases (R-protein-glutamine γ-glutamyltransferases; E. C. 2.3.2.13) comprise a family of Ca2+-dependent acyl-transferases that can catalyze the transamidation or deamidation of protein-bound glutamine residues which can lead to natural cross-links through the formation of an isopeptide bond between the side chains of glutamine and lysine. This PTM is known to limit protein degradation by conformational changes and modification of protease-labile Lys residues. There are nine mammalian TGMs of which TGM2 is the most ubiquitously expressed isoform. This isoform is predominantly localized in the cell cytosol but can also be found associated with the plasma membrane. Furthermore, it can be secreted by unknown mechanisms after P2X7 receptor activation. The enzymatic activity of TGM2 is normally silent but during mechanical injury it becomes activated and functions as a wound healing enzyme by stabilizing extracellular matrix (ECM) and cell-ECM interactions. Another process where TGMs are important is the morphogenesis of the skin. Here, TGM1, 3 and 5 are involved in the formation of the stratum corneum by cross-linking the envelope precursors such as involucrin and involucrin.

Whether transamidation also has a role in the formation and stabilization of intestinal mucus is currently unknown. Mucus and mucins are stored highly concentrated in the granules of goblet cells and expand 1,000-fold in volume upon secretion. If TGM-catalyzed isopeptide cross-links contribute to mucus homeostasis, this processing has to occur after secretion and expansion.

In this work, we analyze if extracellular TGM activity plays a role in organizing the mucus gel in the colon, especially by increasing its stability. To test this hypothesis the abundance of different TGM isoforms was evaluated and their enzymatic activity determined. We found that the formation of Nε-(γ-glutamyl)-lysine isopeptide cross-links in colonic mucus was based on extracellular TGM3-intrinsic activity. Furthermore, mice lacking this TGM isoform secrete a more protease-sensitive MUC2 molecule. In addition, Tgm3-/- mice are less protected against dextran sodium sulfate (DSS) induced colitis. Together, our observations indicate that TGM-catalyzed cross-links are important for the stabilization/homeostasis of colonic mucus and its resistance against disease-inducing conditions.

**Results**

**Transglutaminase 3 is a dominant cross-linking enzyme in the colon.** Firstly, we determined which transglutaminase isoforms were expressed and synthesized in the colonic epithelium. Mouse colon tissue of wild-type (WT) and Tgm knock-out mice were analyzed for protein abundance by using immunohistochemistry (IHC), mass spectrometry (MS) and gel electrophoresis followed by western blot. As we were interested on the impact of transglutaminasins on mucus homeostasis a recently published single-cell transcriptomic study analyzing MUC2-producing goblet cells and non-goblet epithelial cells were mined for the expression profile and protein abundance of the various TGM family members. Analyzing mRNA levels in colonic goblet cells and the remaining epithelial cell populations revealed only transcripts for Tgm2 and Tgm3 genes (Fig. 1a). Next, TGM2 and TGM3 protein abundance determined by mass spectrometry (MS) in these two cell fractions was extracted from the single-cell study. This analysis revealed approximately 10-times lower levels of TGM3 in the goblet cells compared to the non-goblet epithelial cells whereas the abundance of TGM2 was two-three orders of magnitude lower than TGM3 in the respective cell population (Fig. 1b). To evaluate the tissue localization of TGM2 and TGM3, immunohistochemical analyses were performed in WT, Tgm2-/- and Tgm3-/- animals together with the UEA1 lectin staining for the highly glycosylated MUC2 mucin. None of the strains reacted with the anti-TGM2 antibody, confirming the low levels of this isoform (Fig. 1c). This antibody was functional was tested on duodenal tissue sections where a signal for TGM2 was easily observed (Supplementary Fig. S1a). In line with the quantitative data from mRNA expression and protein abundance, both WT and Tgm2-/- animals showed a strong staining for the TGM3 isozyme in the epithelium and as expected no signal in Tgm3-/- mice (Fig. 1d).

As TGM3 lacks a signal sequence, we determined if TGM3 could nonetheless be secreted into the mucus. To answer this, gel electrophoresis and western blot analyses for TGM2 and 3 in colonic mucus were performed. Recombinantly expressed TGM2 and cleaved TGM3 were also loaded as positive controls either non-activated or activated by Ca2+-preincubation (Fig. 1e). The majority of TGM3 was represented by a band migrating around 75 kDa and a weaker signal migrating at approximately 50 kDa in both WT and Tgm2-/- animals. These two bands represent the zymogenic and active form of the enzyme, respectively. Furthermore, several diffuse, but weak, TGM3 signals migrating between 150 and 250 kDa were detected in the WT and Tgm2-/- strains suggesting the self-multimerization of the enzyme and/or its incorporation into substrate proteins. As similar signals were detected in the activated positive control for TGM3, it is likely that self-multimerization occurs in mucus. In contrast, TGM 2 was not detected in the mucus samples of any mouse strain. Specificity of the antibodies used for the respective isoforms was determined by western blot analyses, the anti-TGM3 antibody showed a cross-reactivity <8% against TGM2 and similarly vice versa (Supplementary Fig. S1b). Together the results show that TGM3 is the predominant transglutaminase in the colonic epithelium and the only isozyme detected in the mucus. Furthermore, its expression in goblet cells suggests that its presence in mucus arises at least partly from active secretion and not only from the shedding of cells.
TGM3 activity is present in colonic mucus. Next, we asked if TGM3 is enzymatically active in the colonic mucus and could thereby contribute to its stability by the formation of additional cross-links. For that purpose, a qualitative assay using the incorporation of biotinylated isoform-specific substrate peptides T26 (TGM2) and E51 (TGM3) in mucus was performed. The mucus was incubated with Ca\(^{2+}\) and the respective peptide probe followed by gel electrophoresis and western blot using streptavidin detection (Fig. 2a). Specific incorporation of the two peptides was observed in WT and Tgm2\(^{-/-}\) mucus, but not in mucus from Tgm3\(^{-/-}\) animals. Non-specific signals were observed in all samples, including control reactions where
Fig. 2 Qualitative, quantitative and ex vivo analysis of extracellular transglutaminase activity. a Qualitative determination of calcium-induced transglutaminase activity in colonic mucus. Samples were treated with biotinylated-TGM2 and TGM3 acyl-donor substrates as described in the methods section. The reaction products were separated by SDS-PAGE and subsequently visualized by Western blot using IR680LT-labeled streptavidin on an infrared imager. Non-specific signals from endogenously biotinylated proteins were marked with a triangle. A representative example of three biological replicates per mouse strain is shown. b Qualitative determination of intrinsic transglutaminase activity in colonic mucus. The samples were treated and analyzed as described in (a) without calcium addition. A representative example of three animals per mouse strain is shown. c Detection of putative acyl-donor proteins in mucus. Samples from the different mouse strains were incubated in the presence of 5-Biotinyl-pentylamine (5-BP) for 1 h at 37 °C. Control reactions and detection of reaction products were performed as described in (a). n = 3. d Quantitative determination of transglutaminase activity in colonic mucus. TGM activity was determined by the incorporation of TGM2 (T26) and TGM3 (E51)-specific peptides or a promiscuous acyl-donor peptide (A25) into casein as described in the “Methods” section and subsequent normalization against the respective protein concentration. Colored data points mark activities of individual animals (n ≥ 4). Data present mean ± standard deviation. Source data are provided as a source data file. e-h Ex vivo analysis of transglutaminase activity. Tissues were mounted in a perfusion chamber as illustrated (e) and transglutaminase activity probed with the glutamine-donor peptide E51 coupled to FITC (magenta) for 30 min at 37 °C. After washing away non-incorporated peptide the tissue specimen were analyzed by confocal microscopy. Mucus and nuclei were counterstained with the UEA1 lectin coupled to rhodamine (green) and the Calcein violet stain (blue) respectively. The top panels show Z-stacks of the explant with (left) or without (right) the UEA1 counterstain. The bottom panels show x/y projections of the indicated area from the respective Z-stack on top. Colonic specimen from WT mice (f), Tgm3−/− mice (g) or WT mice in the presence of the pan-TGM inhibitor Z-DON (h) were probed for E51 incorporation. The scale bar corresponds to 50 μm. Three animals per mouse strain were analyzed.
transglutaminase activity was inhibited by iodoacetamide (IAA). These bands represent likely endogenously biotinylated proteins as for example pyruvate-carboxylase. Thus, the detected cross-linking activity in the mucus arises from TGM3-mediated catalysis. To analyze if endogenous mucus contains sufficient Ca\(^{2+}\)-ions for the activation of TGM3, the experiment was repeated without calcium addition. Similar results as with exogenous Ca\(^{2+}\)-addition were obtained, indicating the presence of intrinsic extracellular transglutaminase activity in colonic mucus (Fig. 2b). These results suggest that endogenous acyl-acceptor protein substrates are present in colonic mucus. However, the formation of a transglutaminase-catalyzed cross-linked mucus gel network also requires the presence of acyl-donor proteins. Therefore, the Ca\(^{2+}\)-free experimental set-up was modified by replacing the glutamine-donor with the primary amine 5-Biotinylpentalamine (5-BP) as acyl-acceptor. Similar to the results from the acyl-donor experiments, specific signals were detected when the acyl-acceptor compound was added to mucus of WT and Tgm2\(^{-/-}\) animals, but not in the Tgm3\(^{-/-}\) mucus or when IAA was added (Fig. 2c). Together, the results show that colonic mucus contains intrinsically, active TGM3 as well as both acyl-acceptor and -donor substrates allowing transamidating reactions to take place.

To quantify the intrinsic transamidating activity in colonic mucus, a colorimetric assay for the incorporation of a TGM-mucus into casein was performed (Fig. 2d). A natural cross-linking activity in WT mucus of \(\approx 8 \pm 2\) U/mg for the promiscuous substrate was determined. Substitution with the TGM3-specific substrate E51 led to a 1.5-fold increase \((=12 \pm 4\) U/mg) of the transamidating activity, whereas a residual activity of 0.8 \(\pm 0.3\) U/mg was observed for the TGM2-specific substrate. However, no measurable activity could be obtained in the Tgm3\(^{-/-}\) mucus as the detected values were below the limit of detection for our assay (Fig. 2d, Supplementary Fig. S2). Blocking of the TGM-reaction with Z-DON led to an almost complete (88\%) inhibition for the promiscuous peptide A25. In line with our other results (Fig. 1, Fig. 2a–c), the natural cross-linking activity was related to TGM3 as the use of the TGM2-specific substrate T26 led to less than 10% transglutaminase activity compared to the TGM3-specific substrate in WT animals and was also below the limit of quantification of this assay. These experiments further demonstrated substantial intrinsic transamidating activity in colonic mucus of WT animals, but not in Tgm3\(^{-/-}\), as addition of extra Ca\(^{2+}\) was not required.

The intrinsic mucus transamidating activity of TGM3 was further studied using an ex vivo approach where the distal colon from WT and Tgm3\(^{-/-}\) animals were mounted in a perfusion chamber and the fluorescently labeled glutamine-donor probe E51 was added and its incorporation monitored (Fig. 2e). Figure 2f–h shows the confocal microscopic analyzes of E51 incorporation in the respective tissue/mucus specimen in the x/z plane (top panels) and snap shots of probe incorporation of the x/y plane inside the mucus (bottom panels). A homogeneous punctuated pattern of E51 fluorescence was observed throughout the whole mucus layers of WT animals (Fig. 2f and Supplementary Movie M1). However, when Tgm3\(^{-/-}\) mice were analyzed in the same way, the incorporation was dramatically reduced and limited to shedding epithelial cells (Fig. 2g). A similar lack of incorporation in WT animals was observed in the presence of the transglutaminase inhibitor Z-DON\(^{23}\) (Fig. 2h). These results demonstrate extracellular TGM3 activity ex vivo. Together these results show that the colonic mucus contains natural acyl-donor and acyl-acceptor substrates together with intrinsic TGM3-mediated transamidating activity.

Loss of TGM3 alters biochemical properties of mucus/MUC2. The MUC2 monomer is a large glycoprotein with a mass of around 2.5 MDa (Fig. 3a). It is the most abundant constituent of colonic mucus and is thus a potential target for TGM3-mediated cross-linking, something that could influence its biochemical properties. Colonic mucus from WT, Tgm2\(^{-/-}\) and Tgm3\(^{-/-}\) mice was isolated and disulfide bonds reduced followed by separation via composite agarose-PAGE (AgPAGE) and detected by in-gel immunostaining using anti-MUC2C3 antibody (Fig. 3b). WT and Tgm2\(^{-/-}\) showed two identical diffuse fast-moving bands assumed to be MUC2 monomeric bands (WT-M) and several additional slow-moving and heavily stained bands for higher oligomers. This was in contrast to Tgm3\(^{-/-}\) mucus where MUC2 was seen as a faster migrating diffuse band (Fig. 3b, Tgm3\(^{-/-}\)-M) along with two slower migrating bands similar to WT monomer. These differences in the electrophoretic migration pattern suggest that Tgm3\(^{-/-}\) MUC2 is qualitatively different to that of WT and Tgm2\(^{-/-}\), and argues for TGM3-mediated isopeptide bond modification of MUC2.

As isopeptide bonds can prevent proteolytic cleavage and secreted mucus is normally exposed to numerous endogenous and bacterial proteolytic enzymes, we hypothesized that the different size of MUC2 formed in Tgm3\(^{-/-}\) mice was a result of protease-catalyzed degradation in vivo. To test this hypothesis, colonic mucus of WT and Tgm3\(^{-/-}\) mice was first isolated and solubilized by reduction with dithiothreitol. The resulting samples were treated with the serine protease LysC, followed by the separation of the reaction products via composite AgPAGE and Alcian Blue staining of the heavily glycosylated and protease-resistant MUC2 domains (PTS sequence). All three strains showed three identical intensely stained bands after LysC treatment (Fig. 3c). Interestingly, this band pattern was also observed in the non-treated Tgm3\(^{-/-}\) mice, but not in the WT or Tgm2\(^{-/-}\) animals. This could suggest that the faster migrating MUC2 bands in the non-treated Tgm3\(^{-/-}\) animals represent products that have been already degraded in vivo. To confirm this, the fastest MUC2 migrating bands from the non-treated WT (WT-M) and Tgm3\(^{-/-}\) (Tgm3\(^{-/-}\)-M) samples were excised from the gels (Fig. 3b) followed by mass spectrometric analyses of their tryptic/AspN peptides. The peptide coverage of the MUC2 sequence of three biological replicates is summarized in a heat-map shown in Fig. 3d. The WT monomers showed peptides from all domains except the PTS as expected. Interestingly, the Tgm3\(^{-/-}\) MUC2 molecule showed almost exclusively peptides from the central CysD2 domain (Fig. 3a, d). The vWD4 domain was weakly covered in both mouse strains explaining the anti-MUC2C3 staining (Fig. 3b). As the fastest migrating bands in the Tgm3\(^{-/-}\) mucus were stained by Alcian Blue and have masses larger than 460 kDa, these bands must also include the two mucin domains surrounding CysD2. These PTS1 and PTS2 sequences are highly glycosylated, resistant to proteolytic enzymes, and not identifiable by mass spectrometry (Fig. 3a). Thus, the MUC2 mucin in the Tgm3\(^{-/-}\) mice is suggested to be already degraded in vivo due to it being more susceptible to degradation in the colon lumen. In order to explore if bacterial or host proteases are responsible for this degradation of MUC2 WT and Tgm3\(^{-/-}\) mice were cohoused and an antibiotic cocktail was supplied via the drinking water for four days. This short treatment led to an approximately 100-fold reduction of bacterial load as determined by the 16S rDNA content in the fecal pellet (Supplementary Fig. S3a). After the treatment the electrophoretic migration pattern of MUC2 was analyzed. Under these conditions no difference between WT and Tgm3\(^{-/-}\) animals could be detected (Supplementary Fig. S3b). This data suggests that the degradation of MUC2 in TGM3-deficient mice is mainly driven by the microbial proteases.
Fig. 3 Loss of TGM3 causes biochemical alterations of MUC2 and mucus. 

a Schematic figure of human and mouse MUC2. Protein domains excluding the signal sequence are shown. Abbreviations correspond to vWD, von-Willebrand D; CysD, cysteine-rich domain; PTS, Proline-Serine-Threonine rich becomes mucin domain after O-glycosylation; vWC, von-Willebrand C; CK, Cystine Knot. 

b MUC2 mono- and oligomers from WT, Tgm2−/− and Tgm3−/− colonic mucus separated by composite AgPAGE and stained by in-gel immunodetection (n = 3).

c Limited proteolysis of MUC2 by Lys-C. Mucus was incubated in the absence or presence of Lys-C followed by composite AgPAGE analysis and staining with Alcian blue (n = 3). 

d MUC2 sequence coverage. MUC2 domains are organized from the N- to C-terminus on the ordinate. The PTS domains were excluded as they cannot be analyzed due to their glycosylation heterogeneity. Non-treated MUC2 monomers (WT-M and Tgm3−/−-M) as indicated in (c) were analyzed by MS and sequence coverage color-coded (n = 3). Source data are provided as a source data file.

e Detection of transglutaminase reaction products. Example of an intramolecular isopeptide cross-link solely detected in MUC2 from WT animals. MS2 fragment spectrum of the parent ion [M + 2H]2⁺ 775.44 is shown. B-ions are labeled red and y-ions blue. The parent ion is labeled green.

f Analysis of MUC2 polymerization. Following precipitation of insoluble MUC2 by centrifugation the absorbance of soluble material was recorded at 600 nm. (n = 3). Data are presented as mean ± standard deviation. A two-sided t-test between WT and Tgm3−/− samples was performed p = 0.0738.

g Analysis of mucus hydrophobicity. Melting curves were recorded as described in the methods section. Graph shows the mean of three animals per strain. 

h, i Pronase treatment of colon explant from WT (h) and Tgm3−/− (i) mice. Explants were mounted in perfusion chamber (Fig. 2e) and treated with pronase. Mucus surface was visualized by addition of fluorescently labeled beads, epithelium was counterstained with Syto9. The upper panels show isosurfaces of tissue (green) and beads (red) over time. Lower panel shows the distribution of beads in relation to tissue over time as violin plot. Black bars represent median bead position. Dashed lines represent the 25% quartile. n = 3. (Scale bars = 50 µm; OM = outer mucus; IM = inner mucus).
The most likely explanation for the more degraded MUC2 in Tgm3−/− mice is the loss of protective transglutaminase-catalyzed isopeptide bonds. To search for such bonds, we mined the mass spectrometry data sets for the presence or absence of such cross-links. An example of an intramolecular cross-link connecting Gln 2503 with Lys 2508 is shown in the mass spectrum (Fig. 3e). This intramolecular cross-linked peptide was only detected in MUC2 from WT, but not in Tgm3−/− animals. This isopeptide bridge is located between the vWC2 domain and the cysteine-knot (CK) domain (Fig. 3a). There are likely several additional cross-links and this isopeptide-bridged peptide is only one example, but its absence in Tgm3−/− MUC2 supports this interpretation.

As non-reduced secreted MUC2 polymers in the intestine are known to be insoluble in guanidinium chloride due to isopeptide bonds formed intracellularly24, we asked if TGM3-mediated isopeptide cross-links contributed to this property. To address this question, insoluble mucus from WT and Tgm3−/− mice was precipitated by centrifugation and the turbidity of soluble material in the supernatant was recorded (Fig. 3f). The turbidity of the samples from Tgm3−/− animals was increased by approximately 30% when compared to WT and Tgm2−/− strains. This result further supports the idea that disintegration of the TGM3 enzyme.

This result further supports the idea that disintegration of the TGM3 enzyme.

Mucins have been shown to attach to hydrophobic surfaces25. We hypothesized that natural isopeptide cross-links might contribute to this biophysical property and thus analyzed the hydrophobic character of colonic mucus by using a thermal fluorescent shift assay. Colonic mucus mixed with the hydrophobic dye SyproOrange was subjected to a linear temperature gradient and the fluorescence measured (Fig. 3g). At higher temperatures (>50 °C) the Tgm3−/− mucus showed an increased fluorescence in relation to WT, indicating an increased exposure of hydrophobic protein parts. Preincubation of Tgm3−/− mucus with recombinant TGM3 partly normalized the mucus. It can be suggested that TGM3-mediated isopeptide bonds in WT mucus prevented the unfolding of its constituents.

Mucin processing and tissue secretory responses were assessed using ex vivo mucus measurement assays. Using this approach, we detected no differences in baseline mucin growth rate or carbachol-induced secretory responses between WT and Tgm3−/− tissues (Supplementary Fig. S4a). A similar approach can be used to measure mucus barrier function by applying bacteria−/− mice to a model of colitis. We have previously shown that the reduction-insensitive MUC2 mucin in the Tgm3−/− animals. Nonetheless, we hypothesized that lack of TGM3 would affect mucus barrier stability and thus treated colonic tissue from WT and Tgm3−/− animals with pronase. In WT animals and before addition of pronase to Tgm3−/− tissue, the fluorescent beads remained on top of the mucous layer (Fig. 3h and Supplementary Movies M2 and M3). However, after pronase treatment of Tgm3−/− explants, a progressive decrease in mucus thickness was observed and the beads were more easily washed away and/or penetrated down to the epithelial surface indicating that Tgm3−/− mucus was less protected against proteolytic attack (Fig. 3i and Supplementary Movie M3).

The observed defects of Tgm3−/− mucus suggest that its normal barrier function is compromised and that the normal organization of an inner, attached layer devoid of bacteria and the outer layer harboring the commensal flora is disturbed. This hypothesis was addressed by a combined fluorescent in situ hybridisation (FISH)/MUC2 staining in these mice. Whereas tissue sections from WT animals showed a stratified organized inner mucus layer, the mucus of Tgm3−/− mice had a more disrupted appearance and seemed to be more detached from the epithelium. Furthermore, the separation distance between bacteria and the tissue surface was decreased and the microorganisms were sometimes in close contact with the epithelium (Supplementary Fig. S5).

Tgm3−/− mice are more susceptible to early DSS-induced damage. The altered biochemical properties of mucins and its higher susceptibility to proteolytic degradation in the absence of TGM3 activity suggested that Tgm3−/− mice could be more susceptible to dextran sodium sulfate (DSS) induced colitis. To test this, sex- and age-matched cohoused Tgm3−/− and WT animals were challenged with DSS. The body weight of WT mice increased during the first four days whereas the Tgm3−/− animals started to lose weight from day three and showed on trend decreased body weights compared to WT mice until day 6 (Fig. 4a). This was reflected by an earlier detection of occult blood in the feces of Tgm3−/− mice one day after the start of the experiment (Fig. 4b). Consequently, the Tgm3−/− animals showed a significant raised disease activity index score (DAI) from days two through five after the start of the DSS treatment (Fig. 4c). Higher DAI was maintained in the Tgm3−/− compared to WT animals until day 6, when the colitis also became established in the WT animals. Finally, 50% of the Tgm3−/− animals had to be sacrificed at day 6 or 7, compared to 10% of WT mice, due to suffering and loss of weight following the ethical permit (Fig. 4d). Furthermore, the colon length of Tgm3−/− mice was reduced to 88% of the WT length after 7 days of DSS treatment (Fig. 4e, f). Histopathological analysis of the colonic tissue after eight days of DSS treatment revealed the loss of crypts and an extensive infiltration of immune cells in both strains. These effects were more pronounced in the distal colon (Fig. 4g). However, histological examination of Hematoxylin/Eosin-stained tissue by a blinded pathologist did not detect significant differences between the two animal strains at the end of DSS treatment. DSS has previously been shown to disrupt the mucus layer properties26 and mice lacking the MUC2 mucin are very susceptible to disease after only one day of DSS treatment24. The early onset of DSS effects in the Tgm3−/− supports the conclusion that the colonic mucus is defective in these animals. When colonic tissue was analyzed by immunohistochemistry for TGM2, this isozyme that was absent in non-treated WT and Tgm3−/− animals was disrupted appearance and seemed to be more detached from the epithelium.
Histological analysis of DSS-treated WT and Tgm3−/− mice was performed using the UEA1 lectin (green) and the Hoechst stain (gray). Nuclei were stained using the Hoechst stain (gray).

The graph summarizes the probability of survival of the two mouse strains (filled bars) and the percentage of the initial body weight at the ethical endpoint (scatter plot; two-tailed Wilcoxon test, *p = 0.0137). Two litters per strain were analyzed independently representing ten animals in each group. e-f Colon length changes of DSS-treated WT and Tgm3−/− mice. At the ethical endpoint, animals were sacrificed and the colon length of each animal measured. A representative colon of WT and Tgm3−/− animals is shown in (e). f Normalized colon length of DSS-treated WT and Tgm3−/− mice. The graph shows the summary of two litters per strain analyzed independently representing ten animals in the WT and nine animals in the Tgm3−/− group (p = 0.1214). g Histological analysis of DSS-treated WT and Tgm3−/− mice. Representative Alcian Blue-Periodic Acid Schiff-stained sections from proximal (PC) and distal colon (DC) of WT and Tgm3-deficient animals are shown (n = 5). The black scale bar corresponds to 100 μm. h Immunohistochemical analysis of WT and Tgm3−/− mice for the presence of TGM2 after DSS treatment. Tissue specimens from WT and Tgm3−/− animals were probed with an anti-TGM2 antibody (red) and the UEA1 lectin (green). Nuclei were stained using the Hoechst stain (gray). n = 5. The white scale bar corresponds to 30 μm.

Recent reports have shown that TGM2 was extracellularly inactive and can be activated after injury or stress\textsuperscript{27,29}. Here, we were able to demonstrate intrinsic, extracellular transglutaminase activity in both the WT and Tgm2−/− mouse strains, but its absence in Tgm3−/− animals. In addition, the obtained information showed the presence of natural acyl-donor and acceptor substrates in colonic mucus thereby implying the possibility of in vivo isopeptide-based cross-linking of different mucus components. Furthermore, transglutaminase activity could be detected without the addition of calcium, showing that extracellular transglutaminase activity is intrinsic to the large intestinal mucus. Since a > 90% reduction in TGM activity was observed when the TGM2-selective substrate T26 was used in a quantitative assay and no activity was found in the Tgm3−/− animals, we can conclude that the transamidation activity of mucus is almost exclusively dependent on TGM3 in colon. This is in line with the shown absence of TGM2 protein. In an ex vivo assay, a punctuated...
incorporation of the specific TGM3 peptide substrate E51 in colonic mucus was observed confirming our in vitro observations. However, it was not possible to perform the ex vivo mucus incorporation approach under Ca\(^{2+}\)-free conditions since the normal cellular signaling of the tissue depends on an extracellular calcium pool. This is reflected by measurements of the luminal calcium concentrations in the gut which vary between 5 and 20 mM depending on the feed state\(^ {30,31}\) whereas the concentration in the used buffer was 1.3 mM representing the physiological luminal calcium concentration\(^ {32}\). Given that only 20% of the daily calcium intake is resorbed, mainly in the small intestine, the luminal Ca\(^{2+}\)-concentration in the colon should be sufficient to occupy the second and third Ca\(^{2+}\)-binding site of TGM3 necessary for its activation\(^ {33,34}\). Furthermore, TGM3 is expressed and synthesized in goblet cells, a secretory cell lineage whose secretory granules contain high calcium concentrations for the packaging of the MUC2 mucin. Secretory granules can contain calcium concentrations of up to 40 mM\(^ {35}\). The pH in goblet cell granule is acidic and the Ca\(^{2+}\)-ions are bound to MUC2 and the other stored molecules. After secretion, the pH rises, and free Ca\(^{2+}\)-ions will become available. In addition to goblet cells, neighboring enterocytes could also contribute to the TGM3-mediated mucin stabilization after their shedding and subsequent release of their cellular content as this acyl-transferase was also abundant in these cells. For the activation of TGM3, the Ca\(^{2+}\)-binding sites must be occupied and thezymogenic form of TGM3 needs to be cleaved in the loop harboring amino acids 462-469. For this to take place, CysD2 domain of MUC2 is occupied and the zymogenic form of TGM3 needs to be cleaved by Ca\(^{2+}\)-ions. For this to take place, CysD2 domain was lost and the first CysD2 domain that is located between them, intact (Fig. 3a). Thus, leaving the central part of the MUC2 mucin comprising approximately 1,300 amino acids as well as most of the MUC2 mucin domains to proteolytic cleavage is due to the high glycosylation of the mucins linking enzyme acting on the expanded secreted mucus and by already displaying defects after only two days of treatment. The early onset suggests direct effects on mucus that are likely explained by the decreased intermolecular cross-links in the mucus of Tgm3\(^{-/-}\) mice. Less cross-links will, as shown here, make the mucus more susceptible to proteolytic degradation and detachment leading to a faster mucus removal by intestinal peristalsis. Interestingly, two transcriptomic studies using either the 2,4,6-trinitrobenzene sulfonic acid or the adoptive T-cell transfer colitis model detected TGM3 downregulation after the establishment of the disease, thereby suggesting an impact of this enzyme for a healthy gut\(^ {10,41}\). In contrast to non-treated mice, both the WT and Tgm3\(^{-/-}\) mice synthesized the TGM2 enzyme in their colonic mucosa after DSS treatment. This might reflect a role for TGM2 in wound healing as suggested previously\(^ {18,27}\). As mucus can be regarded as our ‘inner skin’ it is not surprising that a weakened mucus barrier in the Tgm3\(^{-/-}\) mice could be regarded in analogy with the TGM3 function in the skin where earlier observations have shown that these animals have an impaired skin barrier\(^ {42}\).

This study identifies TGM3 as an important natural cross-linking enzyme acting on the expanded secreted mucus and by this contributing to the stabilization of the colonic mucus gel network. The MUC2 mucin and other mucus components are secreted into the harsh luminal environment where proteases from the host, the commensal bacteria, and eventually from pathogens reside. The TGM3-catalyzed formation of isopeptide bond cross-links strengthens the mucus barrier and thereby increase the mucus protection of the colonic epithelium. However, further studies are required to more precisely understand the molecular details of the role of transglutaminases for the mucus structure. For example, as there exists an inverse gradient of serine proteases deciphered an altered phenotype in Tgm3\(^{-/-}\) animals in an ex vivo bead penetration assay. In this approach, the mucus layer seemed to be more disintegrated and less organized allowing the bacteria-mimicking beads to reach the epithelium suggesting a compromised barrier function. We also obtained direct experimental support of this hypothesis by administering DSS to WT and Tgm3\(^{-/-}\) animals. DSS quickly disintegrates the inner colon mucus layer allowing bacteria to reach the epithelium and trigger inflammation typically observed after five days\(^ {26}\). DSS treatment showed that the Tgm3\(^{-/-}\) mice were more susceptible and already displayed defects after only two days of treatment. The observed intrinsic, extracellular transglutaminase activity led us speculate about the putative functional impact of the natural cross-links in colonic mucus. The comparison of mucus from WT and Tgm3\(^{-/-}\) mice provided direct experimental evidence that the loss of TGM3 led to important biochemical alterations of the dominant mucus skeleton protein MUC2. We observed an extensive degradation of the polypeptide as the N-terminal part with the first three vWD and the first CysD domain was lost comprising approximately 1,300 amino acids as well as most of the C-terminus. Thus, leaving the central part of the MUC2 mucin consisting of the two highly glycosylated PTS sequences linked via O-linked glycans resulting in steric hindrance to protease degradation\(^ {35}\). Another feature of MUC2 that was affected in Tgm3\(^{-/-}\) mice is its solubility. MUC2 polymers become insoluble during their transport through the later stages of the secretory pathway\(^ {24}\). In our turbidity assay, an effect on the MUC2 gel network was indicated by an increased optical density in the mucus supernatant from Tgm3\(^{-/-}\) mice. This suggests more soluble MUC2 in this mouse strain. In addition to its solubility, the hydrophobicity of MUC2 was also altered in the absence of TGM3. The assay showed an increased exposure of hydrophobic patches in partly purified MUC2 from Tgm3\(^{-/-}\) animals compared to WT animals upon heat-induced denaturation. This may reflect that the N\(^{-}\)(γ-glutamyl)-lysine bonds in WT-MUC2 stabilize the protein. This phenomenon was partially reversed by reinoculating the Tgm3\(^{-/-}\) mucus with recombinant TGM3, supporting the impact of isopeptide bonds on this biophysical parameter. Our observations are consistent with previous studies showing that isopeptide bonds can stabilize bacterial pil proteins in this kind of assay\(^ {38,39}\). However, the insoluble nature of the MUC2 mucin makes it impossible to purify the MUC2 polypeptide in its native conformation, making recording of a specific melting temperature impossible.

In the Tgm3\(^{-/-}\) mice, the shortened and more degraded MUC2 still seems to be sufficient to provide enough protection for the colonic epithelium. This mouse strain behaves normally and shows no obvious signs of colon inflammation under normal conditions. It is likely that the highly O-glycosylated mucin domains of MUC2 are sufficient to trap microorganisms and prevent bacteria from reaching the epithelial cells. However, challenging the system by the addition of a mixture of serine proteases deciphered an altered phenotype in Tgm3\(^{-/-}\) animals in an ex vivo bead penetration assay. In this approach, the mucus layer seemed to be more disintegrated and less organized allowing the bacteria-mimicking beads to reach the epithelium suggesting a compromised barrier function. We also obtained direct experimental support of this hypothesis by administering DSS to WT and Tgm3\(^{-/-}\) animals. DSS quickly disintegrates the inner colon mucus layer allowing bacteria to reach the epithelium and trigger inflammation typically observed after five days\(^ {26}\). DSS treatment showed that the Tgm3\(^{-/-}\) mice were more susceptible and already displayed defects after only two days of treatment. The early onset suggests direct effects on mucus that are likely explained by the decreased intermolecular cross-links in the mucus of Tgm3\(^{-/-}\) mice. Less cross-links will, as shown here, make the mucus more susceptible to proteolytic degradation and detachment leading to a faster mucus removal by intestinal peristalsis. Interestingly, two transcriptomic studies using either the 2,4,6-trinitrobenzene sulfonic acid or the adoptive T-cell transfer colitis model detected TGM3 downregulation after the establishment of the disease, thereby suggesting an impact of this enzyme for a healthy gut\(^ {10,41}\). In contrast to non-treated mice, both the WT and Tgm3\(^{-/-}\) mice synthesized the TGM2 enzyme in their colonic mucosa after DSS treatment. This might reflect a role for TGM2 in wound healing as suggested previously\(^ {18,27}\). As mucus can be regarded as our ‘inner skin’ it is not surprising that a weakened mucus barrier in the Tgm3\(^{-/-}\) mice could be regarded in analogy with the TGM3 function in the skin where earlier observations have shown that these animals have an impaired skin barrier\(^ {42}\).

**Methods**

**Animals.** This study complied with all relevant ethical regulations for animal testing and research. All procedures were approved by the Swedish Board of Agriculture (Jordbruksverket) that answers to the Ministry of Agriculture. The used...
ethic permissions were 2285/19 and 2292/19. C57/BL6N mice were from Taconic. Tgm2−/− mice43 were provided from Oslo University Hospital (Norway). Tgm3−/− mice44 were obtained from the University of Rome (Tor Vergata, Italy). Mice were maintained at 22 °C with light/dark cycles of 12 h each at a humidity of 40–70%. Animals received a standard rodent diet and water was supplied ad libitum.

Antibodies, enzymes, chemicals. If not otherwise specified chemicals were bought from Sigma. For the detection of TGM2 the monoclonal CUB7402 antibody (Thermo Fisher Scientific) was used for both immunohistochemistry (IHC) and Western Blot. TGM3 detection was performed using the polyclonal NBP1-57678 antibody (Novus Biologicals) for both applications. Cross-reactivity of the two antibodies was analyzed by western blot against recombinant TGM2 and 3 (Supplementary Fig. S1b). For IHC detection of TGM2 a goat-a-mouse-IgG1 antibody coupled to AlexaFluor647 (Invitrogen) and a goat-a-rabbit-IgG antibody coupled to AlexaFluor488 (Invitrogen) for TGM3 detection was used. For Western Blot detection of TGM2 and TGM3 a goat-a-mouse-IgG1 antibody coupled to the IRdye 680LT (LI-COR) and a goat-a-rabbit-IgG antibody coupled to AlexaFluor 790 (Invitrogen) were used respectively. The antibody for in-gel immunodetection of MUC2 was from Genetex (GTX100064). Trypsin and AspN were from Promega. LysoTracker Red was from WAKO (Japan). Recombinant TGM2 (T022) and TGM3 (T013) as well as the biotinylated glutamine-donor substrates A25 (B001), T26 (B008), E51 (B009) and the biotinylated amine-donor compound pentamethylene (B002) were bought from Zedira (Germany). The FITC-labeled E51 probe was bought from CovalAb (France). The transglutaminase inhibitor Z-DON38 was from Zedira. Promera was from Merck (Germany). The UEAI1 actin was from Vector Laboratories (CA). Dextran sulfate sodium was from TdB consultany (Sweden). The oligonucleotides for the quantification of the 165 rDNA were synthesized by Eurofins Genomics and had the following sequences: forward primer: 5′-AAATCTCAAAAGAATTGACG-3′ and reverse primer: 5′-CTCCABRCACAGAACGTTACTC-3′. Antibodies, enzymes, chemicals were reconstituted and protected in water under a nitrogen atmosphere. Equal amounts of the mixture were used to analyze the results of each experiment. The gels were stained with 10% Ponceau for 5 min. Reaction products were separated by SDS-PAGE on 4–15% acrylamide-bisacrylamide gels and stained with Coomassie Brilliant Blue R-250.

Immunohistochemistry. Paraffin-embedded tissue sections were deparaffinized with xylene and rehydrated in ethanol solutions ranging from 100% to 30%. Tissue samples were incubated with 1% glycine in PBS for 5 min. Antigen-retrieval was performed by boiling the sections in 10 mM citrate buffer pH 8.0; 150 mM NaCl) to a total volume of 200 µl. The samples were stored until the AlexaFluor647 dye (Invitrogen) was added. Afterwards the antibodies for TGM2 and 3 were added (1:200 diluted in PBS). Antigen-retrieval was performed by boiling the sections in 10 mM citrate buffer pH 8.0; 150 mM NaCl) to a total volume of 200 µl. The samples were stored until the AlexaFluor647 dye (Invitrogen) was added. Afterwards the antibodies for TGM2 and 3 were added (1:200 diluted in PBS). After fixation the sections were stained with Syto 9 (1:500 in Krebs-glucose buffer) and the integrity of the mucus layer was monitored on an upright LSM900 confocal microscope (Zeiss Examiner 2.1) equipped with a ×20 immersion lens (Plan-Apochormat ×20/0.1 DIC 75 mm; Carl Zeiss; Germany). Images were acquired using Zen Black software (Carl Zeiss) and z-stacks were exported to TIFF format using Imaris software. The mucus was fixed in 2.5% glutaraldehyde solution (Extravidin-paraformaldehyde) and incubated with streptavidin coupled to AlexaFluor 647 (FITC) was used for both immunohistochemistry (IHC) and labeled with AlexaFluor 555. The EUB338 probe for the detection of mucus/Muc2 was precipitated by centrifugation at 12,000 g, and Western Blot. TGM3 detection was performed using the polyclonal NBP1-57678 antibody (Novus Biologicals) for both applications. Cross-reactivity of the two antibodies was analyzed by western blot against recombinant TGM2 and 3 (Supplementary Fig. S1b). For IHC detection of TGM2 a goat-a-mouse-IgG1 antibody coupled to AlexaFluor647 (Invitrogen) and a goat-a-rabbit-IgG antibody coupled to AlexaFluor488 (Invitrogen) for TGM3 detection was used. For Western Blot detection of TGM2 and TGM3 a goat-a-mouse-IgG1 antibody coupled to the IRdye 680LT (LI-COR) and a goat-a-rabbit-IgG antibody coupled to AlexaFluor 790 (Invitrogen) were used respectively. The antibody for in-gel immunodetection of MUC2 was from Genetex (GTX100064). Trypsin and AspN were from Promega. LysoTracker Red was from WAKO (Japan). Recombinant TGM2 (T022) and TGM3 (T013) as well as the biotinylated glutamine-donor substrates A25 (B001), T26 (B008), E51 (B009) and the biotinylated amine-donor compound pentamethylene (B002) were bought from Zedira (Germany). The FITC-labeled E51 probe was bought from CovalAb (France). The transglutaminase inhibitor Z-DON38 was from Zedira. Promera was from Merck (Germany). The UEAI1 actin was from Vector Laboratories (CA). Dextran sulfate sodium was from TdB consultany (Sweden). The oligonucleotides for the quantification of the 165 rDNA were synthesized by Eurofins Genomics and had the following sequences: forward primer: 5′-AAATCTCAAAAGAATTGACG-3′ and reverse primer: 5′-CTCCABRCACAGAACGTTACTC-3′. Antibodies, enzymes, chemicals were reconstituted and protected in water under a nitrogen atmosphere. Equal amounts of the mixture were used to analyze the results of each experiment. The gels were stained with 10% Ponceau for 5 min. Reaction products were separated by SDS-PAGE on 4–15% acrylamide-bisacrylamide gels and stained with Coomassie Brilliant Blue R-250.

Collection of colonic mucus. Mice were anesthetized with isoflurane and sacrificed by cervical dislocation. The colon was collected by dissection and opened under a stereo microscope. Fecal pellets were removed using forceps and mucus was gently scraped off from the epithelial surface using a blunt spatula. Mucus that was sticking to the spatula and detached mucus from the epithelial surface was collected using a pipette and subsequently emulsified in TBS buffer (50 mM Tris pH 8.0; 150 mM NaCl) to a total volume of 200 µl. The samples were stored until further use at −80 °C.

Transglutaminase activity assays. Collected mucus samples were separated into the insoluble MUC2 fraction and supernatant by centrifugation (16,000 x g; 30 min; 4 °C). Mucus supernatants (30 µg) were mixed with 50 mM NaCl) to a total volume of 200 µl. The samples were stored until further use at −80 °C.

Colitis induction by DSS. Six- to eight-week-old female wild-type (WT) C57BL/6 and Tgm3−/− mice were cohoused for 4 to 5 weeks. Colitis was induced by adding 3% (w/v) sodium dextran sulfate (DSS) to the drinking water. Mice could drink ad libitum. The mice were sacrificed after eight days or if their body weight dropped by 10% from the initial weight. The probability of survival was defined when mice died or if they showed a body weight loss >10%. The length was measured and its length measured from cecum to anus and subsequently normalized against the initial body weight of the respective animal. Afterwards, the colon was flushed with PBS for the removal of fecal content. The colony was fixed as Swiss rolls in 4% paraformaldehyde and stained for hematoxylin/eosin and Alcian Blue-PAS. The disease activity index (DAI) was calculated as the sum of the combined scores for stool consistency, hematoxylin and weight loss according to the methods of Friedman and coworkers45. The detection of occult blood was performed using the Hemocult Guiafcel Occult Blood Test kit (Beckman Coulter) according to the manufacturer’s instructions. Two litters of each mouse strain with five animals per litter were analyzed.

Composite agarose-PAGE. The separation of MUC2 was performed according to the protocol of Schulz and coworkers49. Briefly, mucus was scraped from mouse colon and emulsified in TBS. Mucus/Muc2 was precipitated by centrifugation at 16,000 x g and 4 °C for 30 min. The mucus was solubilized by the addition of reducing gel-loading buffer (62.5 mM TrisHCl pH 6.8, 2% SDS, 50 mM DTT 20% (v/v) glycerol). 67 µg were separated via SDS-PAGE for 3.5 h at 30 mA. The gels were either stained with Alcian Blue or were used for autoradiography. Alcian Blue-stained gels were scanned on a GelDoc EZ imager using the Image lab™ software (BioRad). For in-gel immunodetection, the gels were fixed in 50% (v/v) 2-Propanol/ 5% (v/v) acetic acid for 15 min and gentle shaking followed by 30 min washing in water. The primary antibody against MUC2 (Genetex; 1:5000) was detected overnight at 4 °C. After washing with PBS-T the membrane was incubated with streptavidin coupled to AlexaFluor 647 (LI-COR, 1:5000) was added for 1 h at ambient temperature. After three to five
extensive additional washing steps, the immunostained gel was scanned with a LiCOR Odyssey Clx instrument and analyzed using the Image Studio lite software (LiCOR).

Thermofluor assay. Mucus from the indicated mouse strains was scraped from their distal colons and emulsified in TBS buffer. Insoluble mucus was washed twice in TBS and recovered by centrifugation (16,000 × g, 4 °C, 30 min). The protein concentration of the supernatant was determined and the mucus pellet was resuspended in 1 ml of a 200-fold stock solution of SyproOrange (Molecular Probes) and subjected to an increasing temperature gradient of 0.5 °C every 30 s from 25 to 99 °C in a CFX96 Real-time system (BioRad). The fluorescence was recorded every 30 s and the fluorescence intensity of the TBS control subtracted. To rescue the properties of mucus from WT mice 1 U recombinant TGM3 and 4 mM CaCl2 were applied to the mucus from Tgm3−/− mice and incubated for 1 h at 37 °C. The reaction was terminated by the addition of 5 mM IAA. The buffer controls for this part of the experiment were treated accordingly and the melting curve recorded as described above. Three animals per strain were analyzed in technical triplicates.

Analysis of MUC2 depolymerization by turbidity measurement. The turbidity of the supernatant from scraped mucus samples was recorded at a wavelength of 600 nm. The spectrophotometer after subtraction of insoluble material centrifugation (10000 × g, 30 min, 4 °C) followed by subsequent normalization against the protein concentration of the respective sample. The mean of the normalized absorbance from WT samples was set to 100% and used as reference point for all samples analyzed. Three animals per mouse strain were analyzed.

Single cell transcriptomic analysis. RNA-seq data were extracted from a recently published study. Briefly, goblet cells and non-goblet cells from the RedMUC2 reporter mouse strain were isolated by FACs as described previously. The bulk RNA-seq data (GSE144436) are deposited in GEO and belong to the superserie GSE144436. The quality of the data was assessed with FastQC (version 0.11.2) and filtered using Prinseq (version 0.20.3). The reads were aligned against the mouse reference genome mm10 with STAR (version 2.5.2b) and the number of mapped reads was calculated with HTSeq (version 0.6.1p1). Data normalization, differential expression and statistical analysis were made with DESeq2 (version 1.14) in R.

In-gel digestion and mass spectrometric analyses. Briefly, protein bands of interest were excised from the gel and washed with 50% acetonitrile and dried in a vacuum centrifuge followed by reduction with 10 mM DTT for 30 min at 56 °C and subsequent alkylation with 55 mM IAA for 30 min at room temperature. Trypsin was added at a ratio of 1:50 and the samples incubated for 12 h at 37 °C. Afterwards, AspN was added at a ratio of 1:50 and the samples incubated for additional 5 h at 37 °C. The digestion was stopped by adding TFA to a concentration of 0.5%. Salt and buffer components were removed by in-house stage tips equipped with C18 resin and the peptides dissolved in 0.1% formic acid. The samples were analyzed on a Q-Exactive mass spectrometer as described earlier.

MS data analysis. MS raw files were transformed into .raw files using the MS convert software. These files were analyzed using the MASCOT search engine (MatrixScience). Searches were performed against the UniProt database (version 06/2017 containing 554515 sequences) and an in-house database (http://www.ncbi.nlm.nih.gov/gene/GOES) and an in-house database (http://proteomecentral.proteomexchange.org) with the dataset identifier PXD002971. The mass spectrometry data for the analyses of MUC2 isozymes was extracted from the study by Nystrom et al.

Statistical analysis. Statistical analyses were performed using the Prism software (version 9.0.1; GraphPad). Turbidity, body weight and colun length were compared using the unpaired t-test with Welch’s correction. DAI scores were compared by multiple unpaired t-tests using the Holm-Sidak correction. The probability of survival was compared using the Wilcoxon test. Significance was accepted when p values were below 0.05. Data are expressed as mean ± standard deviation.

Data availability
All data are available within the article and Supplementary data files, or available from the corresponding author upon reasonable request. Source data are provided with this paper. The proteomics dataset for label-free quantification used has been published and deposited to the ProteomeXchange Consortium (https://proteomexchange.charon.org) with the dataset identifier PXD01527. The mass spectrometry data for the analyses of MUC2 isozymes generated in this study have been deposited to the ProteomeXchange Consortium with the dataset identifier PXD002971 (https://proteomexchange.charon.org). The MASCOT (http://matrixscience.org) and StavroX (https://stavrox.com/) result files are included in the Supplementary data files. The bulk RNA-seq data (GSE144436) are deposited in GEO (https://www.ncbi.nlm.nih.gov/geo/) and belong to the superserie GSE144466 and have been published. Source data are provided with this paper.

Received: 31 May 2021; Accepted: 9 December 2021; Published online: 11 January 2022

References
1. Johansson, M. E. & Hansson, G. C. Immunological aspects of intestinal mucus and mucus. Nat. Rev. Immunol. 16, 639–649 (2016).
2. Rodriguez-Pineiro, A. M. et al. Studies of mucus in mouse stomach, small intestine, and colon: II. Gastrointestinal mucus proteome reveals Muc2 and Muc5ac accompanied by a set of core proteins. Am. J. Physiol. Gastrointest. Liver Physiol. 305, G348–G356 (2013).
3. Atuma, C., Strøgaard, V., Allen, A. & Holm, L. The adherent gastrointestinal mucus gel layer: thickness and physical state in vivo. Am. J. Physiol. Gastrointest. Liver Physiol. 280, G922–G929 (2001).
4. Johansson, M. E. et al. The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria. Proc. Natl Acad. Sci. USA 105, 15064–15069 (2008).
5. Van der Sluis, M. et al. Muc2-deficient mice spontaneously develop colitis, indicating that Muc2 is critical for colonic protection. Gastroenterology 131, 117–129 (2006).
6. Velech, A. et al. Colorectal cancer in mice genetically deficient in the mucin Muc2. Science 295, 1726–1729 (2002).
7. van der Post, S. et al. Structural weakening of the colonic mucous barrier is an early event in ulcerative colitis pathogenesis. Gut 68, 2142–2151 (2019).
8. Svensson, F., Lang, T., Johansson, M. E. V. & Hansson, G. C. The central exons of the human MUC2 and MUC6 mucins are highly repetitive and variable in sequence between individuals. Sci. Rep. 8, 17503 (2018).
9. Hansson, G. C. Mucins and the microbiome. Annu. Rev. Biochem. 89, 769–793 (2020).
10. Godl, K. et al. The N terminus of the MUC2 mucin forms trimers that are held together within a trypsin-resistant core fragment. J. Biol. Chem. 277, 47248–47256 (2002).
11. Javitt, J. et al. Assembly mechanism of mucin and von Willebrand factor polymers. Cell 183, 717–729 e176 (2020).
12. Recktenwald, C. V. & Hansson, G. C. The reduction-insensitive bonds of the MUC2 mucin are isopeptide bonds. J. Biol. Chem. 291, 13580–13590 (2016).
13. Lorand, L. & Graham, R. M. Transglutaminases:.crosslinking enzymes with pleitropic functions. Nat. Rev. Mol. Cell Biol. 4, 140–156 (2003).
14. Folks, J. E. & Finlayson, J. S. The epsilon-((gamma-glutamyl)lysine crosslink and the catalytic role of transglutaminases. Adv. Protein Chem. 31, 1–133 (1977).
15. Eckert, R. L. et al. Transglutaminase regulation of cell function. Physiol. Rev. 94, 383–417 (2014).
16. Adamczyk, M., Griffiths, R., Dewitt, S., Knauper, V. & Aeschlimann, D. P2X7 receptor activation regulates rapid unconventional export of transglutaminase-2. J. Cell Sci. 128, 4615–4628 (2015).
17. Siegel, M. et al. Extracellular transglutaminase 2 is catalytically inactive, but is powerfully activated upon tissue injury. Proc. Natl Acad. Sci. U. S. A. 105, 7161 (2008).
18. Telci, D. & Griffin, M. Tissue transglutaminase (TG2)–a wound response enzyme. Trends Cell Biol. 11, 867–882 (2006).
19. Eckert, R. L., Sturniolo, M. T., Brome, A. M., Ruse, M. & Rorke, E. A. Transglutaminase function in epidermis. J. Invest Dermatol 124, 481–492 (2005).
20. Nystrom, E. E. L. et al. An intercrypt subpopulation of goblet cells is essential for colonic mucus barrier function. Science 372, eabb1590 (2021).
21. Sugimura, Y. et al. Screening for the preferred substrate sequence of TGM-linked (di)peptides of the murine MUC2. J. Biol. Chem. 291, 7170–7179 (2014).
peptide substrates for TGase 2 and Factor XIIIa. J. Biol. Chem. 281, 17699–17700 (2006).

22. Yamasue, A. et al. Identification of a preferred substrate peptide for transglutaminase 3 and detection of in situ activity in skin and hair follicles. FEMS J. 277, 3564–3574 (2010).

23. Schaertl, S. et al. A profiling platform for the characterization of transglutaminase 2 (TG2) inhibitors. J. Biomol. Screen 15, 478–487 (2010).

24. Axelsson, M. A., Asker, N. & Hansson, G. C. O-glycosylated MUC2 monomer and dimer from LS 174T cells are water-soluble, whereas larger MUC2 species formed early during biosynthesis are insoluble and contain nonreducible intermolecular bonds. J. Biol. Chem. 273, 18864–18870 (1998).

25. Kasdorf, B. T. et al. Mucin-Inspired Lubrication on Hydrophobic Surfaces. Biomacromolecules 18, 2454–2462 (2017).

26. Johansson, M. E. et al. Bacteria penetrate the inner mucus layer before inflammation in the dextran sulfate colitis model. PLoS One 5, e12238 (2010).

27. Jeong, E. M. et al. Transglutaminase 2 is dispensable but required for the survival of mice in dextran sulfate sodium-induced colitis. Exp. Mol. Med. 48, e267 (2016).

28. Stamnaes, J., Iversen, R., du Pre, M. F., Chen, X. & Sollid, L. M. Enhanced B-cell receptor recognition of the autoantigen transglutaminase 2 by efficient catalytic self-multimerization. PLoS One 10, e0134922 (2015).

29. Gross, S. R., Balklava, Z. & Grünf. Importance of tissue transglutaminase in repair of extracellular matrices and cell death of dermal fibroblasts after exposure to a solarium ultraviolet A source. J. Invest. Dermatol. 121, 412–423 (2003).

30. Yildiz, H. M., Speciner, L., Oxendemir, C., Cohen, D. E. & Carrier, R. L. Food-associated stimuli enhance barrier properties of gastrointestinal mucus. Biomaterials 54, 1–8 (2015).

31. Di Maio, S. & Carrier, R. L. Gastrointestinal contents in fasted state and post-lipid ingestion: in vivo measurements and in vitro models for studying oral drug delivery. J. Control Release 151, 110–122 (2011).

32. Wongdee, K., Rodrat, M., Teerapornputtakul, J., Krishnamurta, N. & Charezonphandhu, N. Factors inhibiting intestinal calcium absorption: hormones and luminal factors that prevent excessive calcium uptake. J. Physiol. Sci. 69, 683–696 (1999).

33. Ahvazi, B., Kim, H. C., Kee, S. H., Nemes, Z. & Steinert, P. M. Three-dimensional structure of the human transglutaminase 3 enzyme: binding of calcium ions changes structure for activation. EMBO J. 21, 2055–2067 (2002).

34. Ahvazi, B., Boesl, K. M., Edler, W., Baxa, U. & Steinert, P. M. Role of calcium ions in the activation and activity of the transglutaminase 3 enzyme. J. Biol. Chem. 278, 23834–23841 (2003).

35. Yoo, S. H. Secretory granules in isoosmoly-phosphate-dependent Ca2+ signaling in the cytoplasm of neuroendocrine cells. FASEB J. 24, 653–664 (2010).

36. Cheng, T. et al. Cystatin M/E is a high affinity inhibitor of cathepsin V and cathepsin L by a reactive site that is distinct from the legumain-binding site. A novel clue for the role of cystatin M/E in epidermal cornification. J. Biol. Chem. 281, 15893–15899 (2006).

37. Bergstrom, K. et al. Core 1- and 3-derived O-glycans collectively maintain the colonic mucus barrier and protect against spontaneous colitis in mice. Mol. Immunol. 54, 91–103 (2017).

38. Walden, M., Crow, A., Nelson, M. D. & Banfield, M. J. Intracellular isopeptide but not internal thioester bonds confer proteolytic and significant thermal stability to the S. pyogenes pilus adhesin Spy0125. J. Biol. Chem. 287, 87518–87528 (2012).

39. Hagan, B. M. et al. NMR spectroscopic and theoretical analysis of a spontaneously forming Lys-Asp isopeptide bond. Angew. Chem. Int. Ed. Engl. 49, 8421–8425 (2010).

40. Wu, F. & Chakravarti, S. Differential expression of inflammatory and fibrogenic genes and their regulation by NF-kappab inhibition in a mouse model of chronic colitis. J. Immunol. 179, 6988–7000 (2007).

41. Lyons, J. et al. Integrated in vivo multionics analysis identifies p21-activated kinase signaling as a driver of colitis. Sci. Signal. 11, eaan3580 (2018).

42. Bognar, P. et al. Reduced inflammatory threshold indicates skin barrier defect in transglutaminase 3 knockout mice. J. Invest. Dermatol. 134, 105–111 (2014).

43. De Laurenzi, V. & Melino, G. Gene disruption of tissue transglutaminase. Mol. Cell Biol. 21, 148–155 (2001).

44. Frezza, V. et al. Transglutaminase 3 Protects against Photodamage. J. Invest. Dermatol. 137, 1590–1594 (2017).

45. Trigwell, S. M., Lynch, P. T., Griffin, M., Hargreaves, A. J. & Bonner, P. L. An improved colorimetric assay for the measurement of transglutaminase (type II) - (gamma-glutamyl) lysine cross-linking activity. Anal. Biochem. 330, 164–166 (2004).

46. Gustafsson, J. K. et al. An ex vivo method for studying mucus formation, properties, and thickness in human colonic biopsies and mouse small and large intestinal explants. Am. J. Physiol. Gastrointest. Liver Physiol. 302, G430–G438 (2012).

47. Birchunough, G. M., Nystrom, E. E., Johansson, M. E. & Hansson, G. C. A sentinel goblet cell guards the colonic crypt by triggering Nlrp6-dependent Muc2 secretion. Science 352, 1535–1542 (2016).